In the rapidly growing field of cannabinoid and ECS-targeting drug development, developers face challenges in sourcing, procuring, and supplying high-quality APIs that meet regulatory standards. The need for innovative drug delivery techniques and robust clinical trial design is more pressing than ever.
At the 7th CB1, CB2 & Cannabinoid Drug Development Summit, we offer a platform for showcasing your customized systems and innovative solutions. Engage with key stakeholders and decision-makers from NeuroTherapia, Avecho Biotechnology, GB Sciences, and more. Position your CRO, CDMO, supplier, or consulting services prominently to play a crucial role in driving progress.
With opportunities to present, network one-on-one with stakeholders, and elevate brand visibility, explore a tailored partnership package that aligns with your business objectives, ensuring your solution takes center stage.
Cannabinoid Drug Developers are Actively Seeking New Collaborations to:
- Optimize Clinical Trial Efficiency: Streamline clinical trial processes and recruitment strategies in response to the increasing number of cannabinoid-related drugs entering the market.
- Develop Advanced Delivery Systems: Safely and efficiently administer cannabinoid-based therapeutics using sophisticated drug delivery technologies.
- Enhance Drug Formulation Strategies: Explore innovative formulation techniques to optimize the stability, bioavailability, and therapeutic effectiveness of cannabinoid-based drugs.
- Leverage AI for Drug Discovery: Utilize artificial intelligence to accelerate cannabinoid drug discovery and development, improving precision medicine approaches for targeted therapies.
And more!
Why Partner?
Build connections with your target audience and secure new business: Connect with senior decision makers from biotech and pharma increasing their spend in cannabinoid R&D and CBR-targeting therapies.
Elevate your company’s brand awareness: Explore innovative ways to differentiate your brand and establish yourself as the go-to commercial partner for biotech and pharma entering the cannabinoid and ECS-targeting space.
Showcase your solutions and expertise: Capitalize on our highly engaged audience of biopharma stakeholders prioritizing preclinical & clinical research and actively asking for high-level support.
Who Will You Meet?
